vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Wingstop Inc. (WING). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $183.7M, roughly 1.3× Wingstop Inc.). Wingstop Inc. runs the higher net margin — 16.3% vs 11.1%, a 5.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 7.4%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 8.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Wingstop Inc. is an American international fast food chain that primarily sells buffalo wings. Wingstop locations are decorated with a 1930s and 1940s pre-jet aviation theme.
ANIP vs WING — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $183.7M |
| Net Profit | $27.5M | $29.9M |
| Gross Margin | — | 86.5% |
| Operating Margin | 14.1% | 27.4% |
| Net Margin | 11.1% | 16.3% |
| Revenue YoY | 29.6% | 7.4% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $1.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $183.7M | ||
| Q4 25 | $247.1M | $175.7M | ||
| Q3 25 | $227.8M | $175.7M | ||
| Q2 25 | $211.4M | $174.3M | ||
| Q1 25 | $197.1M | $171.1M | ||
| Q4 24 | $190.6M | $161.8M | ||
| Q3 24 | $148.3M | $162.5M | ||
| Q2 24 | $138.0M | $155.7M |
| Q1 26 | — | $29.9M | ||
| Q4 25 | $27.5M | $26.8M | ||
| Q3 25 | $26.6M | $28.5M | ||
| Q2 25 | $8.5M | $26.8M | ||
| Q1 25 | $15.7M | $92.3M | ||
| Q4 24 | $-10.3M | $26.8M | ||
| Q3 24 | $-24.2M | $25.7M | ||
| Q2 24 | $-2.3M | $27.5M |
| Q1 26 | — | 86.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 85.6% | ||
| Q3 24 | — | 85.0% | ||
| Q2 24 | — | 85.4% |
| Q1 26 | — | 27.4% | ||
| Q4 25 | 14.1% | 26.7% | ||
| Q3 25 | 15.9% | 27.9% | ||
| Q2 25 | 6.6% | 25.9% | ||
| Q1 25 | 13.3% | 22.4% | ||
| Q4 24 | -2.3% | 25.9% | ||
| Q3 24 | -13.8% | 24.5% | ||
| Q2 24 | 3.7% | 26.5% |
| Q1 26 | — | 16.3% | ||
| Q4 25 | 11.1% | 15.2% | ||
| Q3 25 | 11.7% | 16.2% | ||
| Q2 25 | 4.0% | 15.4% | ||
| Q1 25 | 8.0% | 53.9% | ||
| Q4 24 | -5.4% | 16.5% | ||
| Q3 24 | -16.3% | 15.8% | ||
| Q2 24 | -1.7% | 17.7% |
| Q1 26 | — | $1.08 | ||
| Q4 25 | $1.14 | $0.99 | ||
| Q3 25 | $1.13 | $1.02 | ||
| Q2 25 | $0.36 | $0.96 | ||
| Q1 25 | $0.69 | $3.24 | ||
| Q4 24 | $-0.45 | $0.91 | ||
| Q3 24 | $-1.27 | $0.88 | ||
| Q2 24 | $-0.14 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $128.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | — |
| Total Assets | $1.4B | $648.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $128.8M | ||
| Q4 25 | $285.6M | $196.6M | ||
| Q3 25 | $262.6M | $237.6M | ||
| Q2 25 | $217.8M | $227.9M | ||
| Q1 25 | $149.8M | $251.4M | ||
| Q4 24 | $144.9M | $315.9M | ||
| Q3 24 | $145.0M | $84.0M | ||
| Q2 24 | $240.1M | $96.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $540.7M | $-736.8M | ||
| Q3 25 | $505.8M | $-702.6M | ||
| Q2 25 | $436.8M | $-686.0M | ||
| Q1 25 | $418.6M | $-715.0M | ||
| Q4 24 | $403.7M | $-675.6M | ||
| Q3 24 | $405.9M | $-447.5M | ||
| Q2 24 | $455.8M | $-437.5M |
| Q1 26 | — | $648.9M | ||
| Q4 25 | $1.4B | $693.4M | ||
| Q3 25 | $1.4B | $721.0M | ||
| Q2 25 | $1.3B | $708.3M | ||
| Q1 25 | $1.3B | $696.8M | ||
| Q4 24 | $1.3B | $716.2M | ||
| Q3 24 | $1.3B | $484.8M | ||
| Q2 24 | $920.8M | $451.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $57.3M | ||
| Q3 25 | $44.1M | $63.9M | ||
| Q2 25 | $75.8M | $6.6M | ||
| Q1 25 | $35.0M | $25.3M | ||
| Q4 24 | $15.9M | $7.7M | ||
| Q3 24 | $12.5M | $69.0M | ||
| Q2 24 | $17.4M | $36.2M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $34.5M | ||
| Q3 25 | $38.0M | $61.7M | ||
| Q2 25 | $71.8M | $-7.8M | ||
| Q1 25 | $32.5M | $17.3M | ||
| Q4 24 | $13.5M | $-8.6M | ||
| Q3 24 | $7.7M | $54.9M | ||
| Q2 24 | $13.0M | $25.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 19.6% | ||
| Q3 25 | 16.7% | 35.1% | ||
| Q2 25 | 34.0% | -4.5% | ||
| Q1 25 | 16.5% | 10.1% | ||
| Q4 24 | 7.1% | -5.3% | ||
| Q3 24 | 5.2% | 33.8% | ||
| Q2 24 | 9.4% | 16.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 13.0% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 1.9% | 8.2% | ||
| Q1 25 | 1.3% | 4.7% | ||
| Q4 24 | 1.3% | 10.1% | ||
| Q3 24 | 3.2% | 8.7% | ||
| Q2 24 | 3.2% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 2.14× | ||
| Q3 25 | 1.66× | 2.24× | ||
| Q2 25 | 8.87× | 0.25× | ||
| Q1 25 | 2.23× | 0.27× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 2.68× | ||
| Q2 24 | — | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
WING
| Royalty revenue, franchise fees and other | $87.5M | 48% |
| Advertising fees | $63.3M | 34% |
| Company-owned restaurant sales | $33.0M | 18% |
